Tools / Trials and research CD38: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Multifunctional transmembrane glycoprotein able to exert enzymatic activities and also to mobilize calcium, to transduce signals, to adhere to hyaluronan and to other ligands.
Drugs that act on it : 5 Approved : 2 In phases 1 to 3 : 3 Sponsors : 4 Who Is On It, and How Far Along Every drug ChEMBL records acting on CD38, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Approved2 Daratumumab Daratumumab SponsorJohnson & Johnson ModalityAntibody ActionInhibitor Open trials233 Isatuximab Isatuximab SponsorSanofi ModalityAntibody ActionInhibitor Open trials71 Phase 31 Felzartamab Felzartamab SponsorBiogen ModalityAntibody ActionInhibitor Open trials8 Phase 22 Mezagitamab Mezagitamab SponsorTakeda Pharmaceuticals USA ModalityAntibody ActionBinding agent Open trials4 HUMAX-IL15 HUMAX-IL15 SponsorNot known ModalityOther ActionInhibitor Open trials0
Modalities Modalities Share Copy link Download image (PNG)Drugs on this target by ChEMBL molecule type.
Antibody 4 80%Antibody Count4 Share80% Other 1 20%Other Count1 Share20%
The Landscape Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 4 of 5 act as: Lymphocyte differentiation antigen CD38 inhibitor; the rest name their own mechanism.
Open Trials The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 28 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted A Study to Learn About the Effects of Felzartamab on Daily Living Activities and Its Safety in Adults With Generalized Myasthenia Gravis (gMG) Ages 18 to 80 Years Old Felzartamab Phase 2 Not yet recruiting Biogen 2026-11-16 A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131 Daratumumab Phase 3 Not yet recruiting Qilu Pharmaceutical Co., Ltd. 2026-11-12 BCMA/GPRC5D Dual-Target CAR-T Cell Immunotherapy for Relapsed/Refractory Multiple Myeloma Daratumumab Phase 1 Not yet recruiting Liping Dou 2026-11-10 QLS4131 Plus Isa-V-CHOP in Newly Diagnosed, HIV-Negative PBL: A Single-Center, Single-Arm, Phase II Study Isatuximab Phase 2 Not yet recruiting Institute of Hematology & Blood Diseases Hospital, China 2026-11-06 Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma Daratumumab Phase 3 Not yet recruiting Keymed Biosciences Co.Ltd 2026-11-02 Sequential Daratumumab Followed by Telitacicept for the Treatment of ABMR After Kidney Transplantation-A Phase IIa Clinical Trial Daratumumab Phase 2 Active, not recruiting First Affiliated Hospital, Sun Yat-Sen University 2026-10-29 A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible Daratumumab Phase 3 Not yet recruiting Janssen Research & Development, LLC 2026-10-29 To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma Isatuximab Phase 3 Not yet recruiting Kite, A Gilead Company 2026-10-29 QLS4131 Plus Isatuximab in Newly Diagnosed Primary Plasma Cell Leukemia Isatuximab Phase 2 Recruiting Institute of Hematology & Blood Diseases Hospital, China 2026-10-29 Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain Amyloidosis Daratumumab Phase 3 Not yet recruiting Regeneron Pharmaceuticals 2026-10-28 Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma Daratumumab Phase 2 Recruiting Tata Memorial Centre 2026-10-23 Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma Daratumumab Phase 2 / Phase 3 Not yet recruiting Alliance for Clinical Trials in Oncology 2026-10-22 A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN) Felzartamab Phase 2 Not yet recruiting Biogen 2026-10-22 F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma Isatuximab Phase 2 Not yet recruiting Institute of Hematology & Blood Diseases Hospital, China 2026-09-18 Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple Myeloma Isatuximab Phase 2 Not yet recruiting Institute of Hematology & Blood Diseases Hospital, China 2026-08-27 Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT Isatuximab Phase 3 Recruiting AstraZeneca 2026-08-14 Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells Isatuximab Phase 2 / Phase 3 Not yet recruiting The Affiliated People's Hospital of Ningbo University 2026-07-29 A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old Felzartamab Phase 2 Recruiting Biogen 2026-07-23 Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic Anemia Isatuximab Phase 1 / Phase 2 Recruiting Institute of Hematology & Blood Diseases Hospital, China 2026-07-20 A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant Mezagitamab Phase 2 Recruiting Takeda 2026-05-29 A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE) Felzartamab Phase 3 Enrolling by invitation Biogen 2026-03-03 A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation Felzartamab Phase 2 Recruiting Biogen 2025-10-21 A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy Mezagitamab Phase 3 Recruiting Takeda 2025-05-09 A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN) Felzartamab Phase 3 Recruiting Biogen 2025-05-08 A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia Mezagitamab Phase 3 Recruiting Takeda 2025-04-29 A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) Felzartamab Phase 3 Recruiting Biogen 2025-04-20 A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia Mezagitamab Phase 3 Recruiting Takeda 2024-12-09 A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) Felzartamab Phase 3 Active, not recruiting Biogen 2024-11-12
Show all 28Diseases Most Associated With It Open Targets association score, 0 to 1; all associations
Plasma cell myeloma 0.63
Neoplasm 0.49
Parkinson disease 0.47
Smoldering plasma cell myeloma 0.36
Autoimmune thrombocytopenic purpura 0.35
AL amyloidosis 0.32
Self-injurious ideation 0.29
Acute leukemia 0.27
Autoimmune encephalitis 0.26 Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4660 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-18. Gene name, function (UniProt P28907 , CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets